In antiheart failure, salidroside can inhibit the protein phosphorylation level of PI3K/AKT/GSK3β pathway and inhibit the protein expression of Col-I and profilin-I in heart failure rats after acute myocardial infarction (AMI), thus reducing the level of myocardial fibrosis and heart failure. Here, PFN1 is linked to heart failure.